Akiva Juroviesky

Mr. Akiva Juroviesky

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMaria Becker
Maria Becker
DGDenis Gorobets
Denis Gorobets
BEBoniface Ezenwata Echefu
Boniface Ezenwata Echefu
AJAkiva Juroviesky
Akiva Juroviesky
ABAnna Beylis
Anna Beylis
Asher OrnoyAsher Ornoy
Asher Ornoy
Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, most studies employ a single dose, and direct comparisons between commonly used regimens are lacking. We therefore compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-like behavior, sociability, and working memory. Prenatal VPA exposure produced non-linear, dose- and sex-dependent effects. Early neurodevelopment was largely preserved, with only mild and transient delays that were most evident after 300 mg/kg. In contrast, later behavioral alterations differed according to dose, sex, age, and behavioral measure. Sociability deficits were stable across doses in males but became more pronounced with age in females, whereas working memory impairment predominated after 600 mg/kg during adolescence and after 300 mg/kg in adulthood. These findings demonstrate that increasing prenatal VPA dose does not simply increase behavioral severity but produces distinct neurodevelopmental trajectories that depend on dose, sex, and developmental stage.

19 October 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
MBMaria Becker
Maria Becker
DGDenis Gorobets
Denis Gorobets
BEBoniface Ezenwata Echefu
Boniface Ezenwata Echefu
AJAkiva Juroviesky
Akiva Juroviesky
ABAnna Beylis
Anna Beylis
Asher OrnoyAsher Ornoy
Asher Ornoy
Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, direct comparisons between commonly used doses are lacking. We compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-related behavior, sociability, and spontaneous alternation. Early development was largely preserved, although VPA300 delayed cliff aversion acquisition. Total ultrasonic vocalization production was unaffected, while selected call types were altered. Later behavioral effects differed across dose, sex, and age. In males, locomotor activity and center exploration were preserved, sociability was reduced by both VPA doses, and spontaneous alternation was reduced by VPA300 at postnatal day 70 (PND70). In females, locomotor activity was reduced by VPA600 at PND30 and VPA300 at PND70, center exploration was reduced by VPA600, and sociability was reduced by VPA300 at both ages and VPA600 at PND70. VPA600 was also associated with greater embryonic mortality. These findings show that the two VPA doses were associated with differing patterns of developmental and behavioral outcomes, without a consistent increase in severity at the higher dose.